BriaCell Doubles Progression-Free-Survival And Reports Clinical Data Of Bria-IMT ASCO 2024

5/24/24 8:05:28 AM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BCTX alert in real time by email

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastases
Median progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies1,2,3
Clinical benefit rate of 55% in evaluable patients includes HR+, HER2+ and TNBC disease - much higher than comparable studies1,2,3

Get the next $BCTX alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$BCTX

Date	Price Target	Rating	Analyst
2/14/2022	$25.00	Buy	HC Wainwright & Co.

More analyst ratings

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA. The accepted abstracts highlight research related to BriaCell's cellular immunotherapy platform, including the Company's ongoing pivotal Phase 3 study of Bria-IMTᵀᴹ in combination with an

3/10/26 7:30:00 AM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL), BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2025 held on March 5, 2026 (the "Meeting"). A total of 48.31% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, co

3/5/26 4:04:34 PM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), are pleased to announce that they have entered into a definitive purchase agreement (the "Purchase Agreement") pursuant to which BriaPro has agreed to purchase BriaCell's exclusive license to develop and commercialize Soluble CD80 ("sCD80") as a biologic agent for the treatment of cancer and other associated assets (the "Transaction"). Background Bri

2/18/26 5:30:00 PM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

$BCTX
Leadership Updates

Live Leadership Updates

View All

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

3/5/26 4:04:34 PM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of

2/5/25 6:15:47 PM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed

1/3/25 5:05:00 PM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell Doubles Progression-Free-Survival And Reports Clinical Data Of Bria-IMT ASCO 2024

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$BCTX

BriaCell Doubles Progression-Free-Survival And Reports Clinical Data Of Bria-IMT ASCO 2024

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$BCTX

$BCTX
Insider Purchases

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

$BCTX
SEC Filings

SEC Form 10-Q filed by BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 25-NSE filed by BriaCell Therapeutics Corp.

$BCTX
Insider Trading

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

SEC Form 4 filed by Williams William V.

$BCTX
Press Releases

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

$BCTX
Analyst Ratings

HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

$BCTX
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

$BCTX
Financials

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

$BCTX
Leadership Updates

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

BriaCell Doubles Progression-Free-Survival And Reports Clinical Data Of Bria-IMT ASCO 2024

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $BCTX

BriaCell Doubles Progression-Free-Survival And Reports Clinical Data Of Bria-IMT ASCO 2024

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $BCTX

$BCTX Insider Purchases

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

$BCTX SEC Filings

SEC Form 10-Q filed by BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 25-NSE filed by BriaCell Therapeutics Corp.

$BCTX Insider Trading

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

SEC Form 4 filed by Williams William V.

$BCTX Press Releases

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

$BCTX Analyst Ratings

HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

$BCTX Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

$BCTX Financials

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

$BCTX Leadership Updates

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

Recent Analyst Ratings for
$BCTX

Recent Analyst Ratings for
$BCTX

$BCTX
Insider Purchases

$BCTX
SEC Filings

$BCTX
Insider Trading

$BCTX
Press Releases

$BCTX
Analyst Ratings

$BCTX
Large Ownership Changes

$BCTX
Financials

$BCTX
Leadership Updates